|Day Low/High||3.27 / 3.37|
|52 Wk Low/High||1.49 / 7.09|
Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
It was good to stand in for Doug Kass today. Lots of lively conversation this Friday (over 200 comments), most of them around the markets as well....:-). The Daily Diary was certainly more interesting than today's market, which ended mixed as it clo...
The first day of trading in the fourth quarter was rough as stocks declined Monday.
Thermo Fisher is looking bullish, while Blue Buffalo goes the other way.
New drugs give small-cap companies opportunity to expand markets and revenues.
The sector seems to be rebounding after tumbling by more than 40%.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Let's look at other attractively valued bets in what is at least a slightly overbought market overall.
These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
A so-called "pyramid strategy" can help you enter the depressed sector.
Biotech's pipeline includes a cancer drug that's close to approval.
Merrimack and Threshold Pharmaceuticals will soon announce catalysts to propel their stocks, says Rob Goldman of Goldman Small Cap Research.
Bob Mulroy, CEO of Merrimack Pharmaceutical, reveals the innovation behind the company's quest to find treatments for cancer.